Net loss (USD)

Stock-based compensation (USD)

Depreciation (USD)

Amortization of right of use asset (USD)

Changes in operating assets and liabilities: Tax receivable (USD)

Changes in operating assets and liabilities: Prepaid expenses and other current assets (USD)

Changes in operating assets and liabilities: Other assets (USD)

Changes in operating assets and liabilities: Accounts payable and accrued expenses (USD)

Changes in operating assets and liabilities: Operating lease liability (USD)

Net cash used in operating activities (USD)

Investing Activities: Purchase of property and equipment (USD)

Net cash used in investing activities (USD)

Financing Activities: Payments of deferred offering costs (USD)

Financing Activities: Proceeds from exercise of stock options (USD)

Financing Activities: Proceeds from sale of common stock, net of offering costs (USD)

Financing Activities: Proceeds from sale of Nexcella common stock (USD)

Financing Activities: Funds received for subsidiary private offering (USD)

Net cash provided by financing activities (USD)

Effect of foreign currency on cash (USD)

Net change in cash and cash equivalents (USD)

Supplemental Disclosures of Cash Flow Information: Income taxes paid (USD)

Supplemental Disclosures of Cash Flow Information: Interest paid (USD)

Supplemental Disclosures of Noncash Financing Information: Establishment of right of use asset and liabilities (USD)

Supplemental Disclosures of Noncash Financing Information: Purchases of property and equipment included in accounts payable and accrued liabilities (USD)

Supplemental Disclosures of Noncash Financing Information: Nexcella shares issued for funds previously received (USD)

Supplemental Disclosures of Noncash Financing Information: Shares issued in subsidiary absorption (USD)

Supplemental Disclosures of Noncash Financing Information: Deferred offering costs charged against proceeds from sale of common stock (USD)

Supplemental Disclosures of Noncash Financing Information: Shares issues for vested restricted stock awards (USD)

Cash and cash equivalents – beginning of period (USD)

Cash and cash equivalents – end of period (USD)

d9322f6cc637a6031e43f2a2c184f89fe92d62fe888fbd5e0e9257481e551826

General and administrative expenses (USD)

Research and development (USD)

Total operating expenses (USD)

Loss from operations (USD)

Interest income (USD)

Total other income (USD)

Total other income (expense), net (USD)

Loss before provision for income taxes (USD)

Provision for income taxes (USD)

Net loss attributable to non-controlling interests (USD)

Net loss attributable to Immix Biopharma, Inc. common stockholders (USD)

Other comprehensive income (loss): Foreign currency translation (USD)

Total other comprehensive income (loss) (USD)

Comprehensive loss (USD)

Comprehensive loss attributable to Immix Biopharma, Inc. common stockholders (USD)

Loss per common share - basic and diluted (USD per share)

Weighted average shares outstanding - basic and diluted (Shares)

8a62b99f662504052eed7eeb9438e2bf5955eb9d2bed281bc7e5c339d75dde8a

Cash and cash equivalents (USD)

Tax receivable (USD)

Prepaid expenses and other current assets (USD)

Total current assets (USD)

Other assets (USD)

Property and equipment, net (USD)

Total assets (USD)

Accounts payable and accrued expenses (USD)

Total current liabilities (USD)

Total liabilities (USD)

Preferred stock, $ 0.0001 par value (USD)

Common stock, $ 0.0001 par value (USD)

Additional paid-in capital (USD)

Accumulated other comprehensive income (USD)

Accumulated deficit (USD)

Treasury stock at cost (USD)

Total Immix Biopharma, Inc. stockholders’ equity (USD)

Non-controlling interests (USD)

Total stockholders’ equity (USD)

Total liabilities and stockholders’ equity (USD)

152ec7bf9eaac8a68aff7a9a2268478fd09b5f019a6229f942615174e6b84e2c

Number of relapsed/refractory AL Amyloidosis patients treated with NXC-201 (patients)

Overall response rate for NXC-201 in relapsed/refractory AL Amyloidosis (percent)

Complete response rate for NXC-201 in relapsed/refractory AL Amyloidosis (percent)

Number of relapsed/refractory AL Amyloidosis patients in our ongoing Phase 1b/2 multi-site NEXICART-2 (patients)

Number of relapsed/refractory AL Amyloidosis patients in our ongoing Phase 1b/2a NEXICART-1 (patients)

0cb8585e5e1f38b18982a9f34a504a2ee2f654f2275fea38e1e92920923c193b

Immix Biopharma Inc (IMMX)

Financials